디지털 병리학 시장 : 유형, 제품 유형, 실험실 처리 능력, 도입 모델, 용도, 최종 사용자별 - 세계 예측(2026-2032년)

The Digital Pathology Market is projected to grow by USD 4.09 billion at a CAGR of 16.05% by 2032.

Digital pathology is reshaping anatomic pathology by converting glass-slide workflows into connected, image-based diagnostic ecosystems. The market centers on whole slide imaging, image management systems, laboratory information system integration, computational pathology, telepathology, and regulated artificial intelligence tools that support pathologists in high-volume clinical and research settings.

Adoption is being driven by sustained growth in oncology testing, expanding precision medicine programs, pathology workforce shortages, and the need for faster subspecialty consultation across distributed health systems. Regulatory milestones have also increased confidence: the U.S. Food and Drug Administration authorized the first whole slide imaging system for primary diagnosis in 2017, and the College of American Pathologists has published validation guidance for clinical whole slide imaging implementation.

For industry vendors, digital pathology is no longer a limited research or education tool. It is becoming an enterprise infrastructure layer for diagnostic quality, workload balancing, biomarker quantification, data-rich pathology archives, and AI-enabled clinical decision support.

Transformative Shifts in the Digital Pathology Landscape

The digital pathology landscape is shifting from scanner-led purchasing to enterprise workflow transformation. Hospitals, reference laboratories, academic medical centers, and pharmaceutical research organizations are evaluating platforms based on interoperability, diagnostic-grade image quality, uptime, cybersecurity, data governance, and integration with LIS, PACS, cloud, and laboratory automation systems.

A second major shift is the move from local deployment to hybrid and cloud-enabled architectures. High-resolution whole slide images generate large data volumes, making storage strategy, compression, retrieval speed, and vendor-neutral image access central to procurement decisions. DICOM-compatible pathology imaging and HL7-based connectivity are becoming increasingly important as pathology converges with radiology, genomics, and oncology informatics.

The competitive landscape is also evolving from hardware differentiation toward end-to-end value. Scanner throughput, z-stack capability, image fidelity, AI readiness, validation support, and global service coverage now influence purchasing decisions as much as device specifications.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is compounding the value of digital pathology by turning whole slide images into structured, searchable, and quantifiable diagnostic assets. Current AI use cases include tumor detection, tissue segmentation, mitotic counting, quality control, workload triage, and biomarker scoring support. In 2021, the U.S. Food and Drug Administration authorized an AI-based tool to help pathologists identify areas suspicious for cancer in prostate biopsy images, signaling the transition from research algorithms to regulated clinical support.

The cumulative impact of AI is strongest when algorithms are embedded into validated workflows rather than deployed as standalone tools. Pathologists remain accountable for diagnosis, while AI can reduce repetitive visual search, improve consistency in quantification, and help prioritize complex or time-sensitive cases.

Responsible adoption requires site-specific validation, human-in-the-loop oversight, dataset diversity, audit trails, cybersecurity controls, and continuous performance monitoring. As foundation models and multimodal pathology systems mature, the highest-value applications will combine image data with clinical, molecular, and treatment-response data.

Key Regional Insights

North America remains one of the most advanced regions for digital pathology adoption, supported by large integrated health systems, academic cancer centers, reference laboratories, established regulatory pathways, and strong investment in computational pathology. The United States leads in regulated clinical adoption, while Canada benefits from provincial telepathology initiatives and geographically distributed care models that support remote consultation across wide service areas.

Europe is progressing through national health digitization programs, cancer network modernization, and regulated in vitro diagnostic frameworks. The United Kingdom has established notable digital pathology deployments within public health-linked networks, while Germany, France, Italy, and Spain are increasing investment in hospital digitization and oncology diagnostics. European Union IVDR requirements are raising expectations for clinical evidence, traceability, and post-market surveillance.

Asia-Pacific is expanding rapidly because of high diagnostic volumes, rising cancer incidence, and strong digital health initiatives in China, Japan, South Korea, India, and Australia. Latin America is led by Brazil and Mexico, where private laboratory networks and urban specialty centers are early adopters. The Middle East, particularly GCC healthcare systems, is investing in smart hospitals and advanced oncology infrastructure, while Africa shows growing telepathology relevance in response to pathologist shortages, geographic access gaps, and the need for remote specialist review.

Key Group Insights

The European Union is shaping digital pathology through harmonized regulatory expectations, cross-border health data initiatives, and hospital digitization funding. EU-wide emphasis on interoperability, IVDR compliance, cybersecurity, and evidence-based procurement is pushing suppliers and healthcare systems to provide transparent validation data, lifecycle support, and traceable clinical performance documentation.

G7 markets are setting the pace for regulated adoption because they combine mature healthcare reimbursement structures, advanced oncology programs, high pathology informatics maturity, and strong academic research capacity. NATO countries show overlapping demand for secure health data infrastructure, resilient medical supply chains, and interoperable digital systems that can support civilian and military medical readiness.

BRICS economies represent a scale-driven opportunity, with China and India offering high-volume diagnostic demand, Brazil strengthening regional laboratory networks, Russia maintaining interest in domestic health technology capacity, and South Africa reinforcing the role of telepathology in specialist access. ASEAN adoption is uneven but promising, with Singapore, Malaysia, Thailand, Indonesia, Vietnam, and the Philippines pursuing digital health modernization at different speeds. The GCC is one of the most active groups for premium healthcare infrastructure, led by Saudi Arabia, the United Arab Emirates, Qatar, and other states investing in oncology centers, smart hospitals, and AI-enabled care delivery.

Key Country Insights

The United States is the most influential digital pathology market because of FDA-authorized systems, large reference laboratories, academic medical centers, and strong investment in pathology AI. Canada is advancing through provincial care models and remote pathology consultation needs, while Mexico is growing through private diagnostics networks and medical tourism-linked specialty care. Brazil is the leading Latin American opportunity, supported by major urban laboratory groups and expanding oncology services.

In Europe, the United Kingdom is notable for public health-linked digital pathology networks and cancer pathway modernization. Germany combines high healthcare expenditure with strong medical technology infrastructure, while France is advancing hospital digitization and oncology diagnostics. Italy and Spain are adopting digital workflows through regional hospital systems and research hospitals, and Russia remains focused on domestic diagnostic capacity and large-scale public healthcare needs.

In Asia-Pacific, China offers scale, domestic scanner development, and hospital digitization momentum, while India has strong demand due to diagnostic volume and pathologist access gaps. Japan emphasizes quality, regulatory rigor, and advanced cancer care, while South Korea combines digital hospital infrastructure with strong medtech innovation. Australia is a mature adopter for telepathology and regional access, particularly where specialist pathology services must cover large geographic distances.

Actionable Recommendations for Industry Leaders

Industry vendors should treat digital pathology as an enterprise transformation program rather than a device purchase. The first priority is a validated roadmap that links scanner deployment, image management, LIS integration, storage architecture, cybersecurity, pathologist training, and clinical governance.

Technology providers should prioritize interoperable platforms, transparent performance data, regulatory readiness, and service models that support multi-site scaling. Healthcare providers should build business cases around turnaround time, subspecialty access, workload balancing, quality assurance, education, and research enablement rather than relying only on direct labor savings.

AI adoption should begin with high-value, narrow use cases such as quality control, triage, or biomarker quantification support, followed by phased expansion after validation. Companies should also establish data stewardship policies, algorithm monitoring, procurement standards, and cross-functional governance involving pathology, IT, compliance, oncology, and executive stakeholders.

Research Methodology

This executive summary reflects a structured secondary and primary research approach aligned with established market intelligence standards. Insights are derived from verified public sources, including regulatory databases, device authorizations, European regulatory frameworks, CAP guidance, peer-reviewed pathology literature, national digital health programs, product documentation, hospital digitization evidence, and clinical implementation studies.

The analysis triangulates demand indicators across clinical adoption, regulatory maturity, installed infrastructure, oncology testing needs, workforce constraints, technology readiness, and procurement behavior. Regional, group, and country insights are assessed through comparable variables such as healthcare expenditure, cancer diagnostics capacity, digital health policy, telemedicine infrastructure, and laboratory consolidation.

Claims are limited to evidence-backed observations and clearly established market patterns. The methodology avoids unsupported market sizing assumptions and emphasizes validated developments in whole slide imaging, AI-enabled pathology, interoperability, and clinical implementation.

Conclusion

Digital pathology is entering a scale-up phase as healthcare systems move from isolated pilots to enterprise imaging strategies. Whole slide imaging, AI-enabled workflow support, cloud-ready image management, and interoperable data infrastructure are becoming core elements of modern pathology operations.

The strongest market opportunities will emerge where technology improves diagnostic access, quality, speed, and consistency without disrupting pathologist accountability. Organizations that invest in validation, interoperability, governance, and change management will be better positioned to capture the clinical and operational value of digital pathology.

As AI and computational pathology mature, the field will increasingly connect tissue images with molecular, clinical, and treatment data. This convergence positions digital pathology as a foundational capability for precision medicine, oncology innovation, and the future of data-driven diagnostics.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Digital Pathology Market, by Type

• 7.1. Human Pathology
• 7.2. Veterinary Pathology

8. Digital Pathology Market, by Product

• 8.1. Hardware
  • 8.1.1. Displays
    • 8.1.1.1. Consumer off the Shelf
    • 8.1.1.2. Medical Grade
    • 8.1.1.3. Professional Grade
  • 8.1.2. Scanners
    • 8.1.2.1. Brightfield Scanners
    • 8.1.2.2. Fluorescence Scanners
  • 8.1.3. Storage Systems
• 8.2. Services
  • 8.2.1. Consulting & Implementation Services
  • 8.2.2. Maintenance & Support Services
  • 8.2.3. Training Services
• 8.3. Software
  • 8.3.1. Image Management Systems (IMS)
  • 8.3.2. Laboratory Information Systems (LIS)
  • 8.3.3. Picture Archiving and Communication Systems (PACS)

9. Digital Pathology Market, by Laboratory Throughput

• 9.1. Low-Throughput
• 9.2. Medium-Throughput
• 9.3. High-Throughput

10. Digital Pathology Market, by Deployment Model

• 10.1. On-Premises
• 10.2. Cloud-Based
• 10.3. Hybrid

11. Digital Pathology Market, by Application

• 11.1. Biomarker Discovery
• 11.2. Disease Diagnosis
  • 11.2.1. Infectious Diseases
  • 11.2.2. Neurology
  • 11.2.3. Oncology
• 11.3. Drug Discovery & Development
• 11.4. Telepathology
• 11.5. Toxicology Studies
• 11.6. Training & Education

12. Digital Pathology Market, by End User

• 12.1. Academic & Research Institutes
• 12.2. Contract Research Organizations
• 12.3. Government & Regulatory Bodies
• 12.4. Hospitals & Diagnostic Labs
• 12.5. Pharmaceutical & Biotechnology Companies

13. Digital Pathology Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Digital Pathology Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Digital Pathology Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. 3DHISTECH Ltd.
• 17.2. Aiforia Technologies PLC
• 17.3. Aignostics GmbH
• 17.4. Akoya Biosciences
• 17.5. Charles River Laboratories
• 17.6. Corista LLC
• 17.7. Danaher Corporation
• 17.8. Deep Bio Inc.
• 17.9. Epredia
• 17.10. F. Hoffmann-La Roche Ltd.
• 17.11. FUJIFILM Holdings Corporation
• 17.12. General Electric Company
• 17.13. Gestalt Diagnostics Ltd.
• 17.14. Hamamatsu Photonics K.K.
• 17.15. Huron Digital Pathology
• 17.16. Ibex Medical Analytics Ltd.
• 17.17. Indica Labs
• 17.18. Koninklijke Philips N.V.
• 17.19. Laboratory Corporation of America Holdings
• 17.20. Mikroscan Technologies, Inc.
• 17.21. Mindpeak GmbH
• 17.22. Motic
• 17.23. Nikon Corporation
• 17.24. Olympus Corporation
• 17.25. OptraSCAN Inc.
• 17.26. Owkin, Inc.
• 17.27. Pathcore Inc.
• 17.28. PathPresenter Corporation
• 17.29. PerkinElmer, Inc.
• 17.30. Proscia, Inc.
• 17.31. Qritive Inc.
• 17.32. Quest Diagnostics Incorporated
• 17.33. Sectra AB
• 17.34. Visiopharm A/S
• 17.35. Xybion Digital Inc.